AU2002327635B2 - Enhancement of learning and memory and treatment of amnesia - Google Patents

Enhancement of learning and memory and treatment of amnesia Download PDF

Info

Publication number
AU2002327635B2
AU2002327635B2 AU2002327635A AU2002327635A AU2002327635B2 AU 2002327635 B2 AU2002327635 B2 AU 2002327635B2 AU 2002327635 A AU2002327635 A AU 2002327635A AU 2002327635 A AU2002327635 A AU 2002327635A AU 2002327635 B2 AU2002327635 B2 AU 2002327635B2
Authority
AU
Australia
Prior art keywords
compound
sub
memory
ltp
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002327635A
Other languages
English (en)
Other versions
AU2002327635A1 (en
Inventor
Wei-Lin Chien
Wen-Mei Fu
Sheng-Chu Kuo
Fang-Yuan Lee
Keng-Chen Liang
Che-Ming Teng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Carlsbad Technology Inc
Original Assignee
Carlsbad Technology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carlsbad Technology Inc filed Critical Carlsbad Technology Inc
Publication of AU2002327635A1 publication Critical patent/AU2002327635A1/en
Application granted granted Critical
Publication of AU2002327635B2 publication Critical patent/AU2002327635B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2002327635A 2001-09-14 2002-09-16 Enhancement of learning and memory and treatment of amnesia Ceased AU2002327635B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32238901P 2001-09-14 2001-09-14
US60/322,389 2001-09-14
US10/242,826 US7049334B2 (en) 2001-09-14 2002-09-13 Enhancement of learning and memory and treatment of amnesia
US10/242,826 2002-09-13
PCT/US2002/029294 WO2003024397A2 (en) 2001-09-14 2002-09-16 Enhancement of learning and memory and treatment of amnesia

Publications (2)

Publication Number Publication Date
AU2002327635A1 AU2002327635A1 (en) 2003-06-05
AU2002327635B2 true AU2002327635B2 (en) 2007-12-13

Family

ID=26935379

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002327635A Ceased AU2002327635B2 (en) 2001-09-14 2002-09-16 Enhancement of learning and memory and treatment of amnesia

Country Status (10)

Country Link
US (1) US7049334B2 (enExample)
EP (1) EP1425011B1 (enExample)
JP (1) JP2005502722A (enExample)
KR (1) KR100889515B1 (enExample)
AT (1) ATE447405T1 (enExample)
AU (1) AU2002327635B2 (enExample)
CA (1) CA2460005C (enExample)
DE (1) DE60234263D1 (enExample)
NZ (1) NZ532022A (enExample)
WO (1) WO2003024397A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077702A1 (en) * 2001-09-14 2004-04-22 Wen-Mei Fu Treatment of nuerodegenerative diseases
JP4499721B2 (ja) 2003-06-30 2010-07-07 ヒフ バイオ，インク． 化合物、組成物および方法
JP2005089457A (ja) * 2003-09-03 2005-04-07 Yung Shin Pharmaceutical Industry Co Ltd 骨成長を促進するまたは骨吸収を阻害するための薬剤組成物
US6984652B2 (en) 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
AU2007276763B2 (en) * 2006-07-24 2011-03-17 University Of Maryland, Baltimore Heme oxygenase inhibitors and methods of therapeutic use
CA2671524A1 (en) * 2006-12-01 2008-06-12 Loma Linda University Medical Center Inhibition of brain enzymes involved in cerebral amyloid angiopathy and macular degeneration

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5240947A (en) * 1992-11-30 1993-08-31 National Science Council 2,3,4,5-substituted furo[2,3-c]pyrazole derivatives
JP2928079B2 (ja) * 1994-02-14 1999-07-28 永信薬品工業股▲ふん▼有限公司 １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途
US7115661B1 (en) * 1999-12-29 2006-10-03 Queen's University At Kingston Methods and compositions for mitigating pain
DE19642255A1 (de) * 1996-10-14 1998-04-16 Bayer Ag Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten
DE19744026A1 (de) * 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
GB9920566D0 (en) * 1999-08-31 1999-11-03 Univ London Screen for axon viability
AU2001234602A1 (en) * 2000-01-26 2001-08-07 Cedars-Sinai Medical Center Method for using potassium channel agonists for delivering medicant to an abnormal brain region and/or a malignant tumor
AR031176A1 (es) * 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina

Also Published As

Publication number Publication date
US20030105149A1 (en) 2003-06-05
EP1425011A4 (en) 2007-09-19
DE60234263D1 (de) 2009-12-17
EP1425011B1 (en) 2009-11-04
JP2005502722A (ja) 2005-01-27
CA2460005A1 (en) 2003-03-27
NZ532022A (en) 2005-12-23
WO2003024397A3 (en) 2003-11-06
EP1425011A2 (en) 2004-06-09
KR20040049307A (ko) 2004-06-11
CA2460005C (en) 2008-12-02
KR100889515B1 (ko) 2009-03-19
US7049334B2 (en) 2006-05-23
ATE447405T1 (de) 2009-11-15
WO2003024397A2 (en) 2003-03-27

Similar Documents

Publication Publication Date Title
JP5702288B2 (ja) Ｎｍｄａレセプターモジュレータ及びその用途
JP4248239B2 (ja) プリン作用性レセプターアンタゴニストとしてのピロロ［２，３−ｄ］ピリミジンおよびそれらの使用
KR20230121808A (ko) 약제학적 활성 화합물로서 칸나비노이드 유도체 및이의 제조 방법
JP2002532393A (ja) エキソ−ｒ−メカミラミン製剤および治療におけるその使用
CN1255854A (zh) 1,2,4－三唑并[1,5－c]嘧啶杂环类似物在制备用于治疗心血管疾病的药物中的用途
JP2004517861A (ja) プリン作動性レセプターアンタゴニストとしてのピラゾロ［３，４−ｄ］ピリミジン誘導体およびそれらの使用
JP2015007096A (ja) 運動障害の予防および／または治療剤
US20090088449A1 (en) 4-acylaminopyridine derivative mediated neurogenesis
EP1425011B1 (en) Enhancement of learning and memory and treatment of amnesia
AU2002327635A1 (en) Enhancement of learning and memory and treatment of amnesia
JP2020509043A (ja) カンナビノイドアゴニストによる認知症の治療
EP3615023B1 (en) Lipoyl-glu-ala for the treatment of neurodegenerative damage caused by traumatic brain injury
ES2643377T3 (es) Composición farmacéutica para prevenir o tratar degeneración macular
WO1995007282A1 (en) Depression remedy
JPH10101566A (ja) 網膜保護剤
EP1512400B1 (en) Treatment of neurodegenerative diseases
WO2009050554A2 (en) Treatment of central nervous system disorders
JP2003238405A (ja) 敗血症の処置に使用される薬剤組成物
US10870633B2 (en) Types of C-3 substituted kynurenic acid derivatives with improved neuroprotective activity
JP2005534665A (ja) うつ病の治療のためのｐｄｅ−ｖ阻害物質及びｎｋ１拮抗薬の組合せ
HK40016595A (en) Lipoyl-glu-ala for the treatment of neurodegenerative damage caused by traumatic brain injury
US20030114483A1 (en) Compositions of chromene cyclooxygenase-2 selective inhibitors and acetaminophen for treatment and prevention of inflammation, inflammation-mediated disorders and pain
JPS5850965B2 (ja) パ−キンソン病治療薬
MX2008010252A (en) 4-acylaminopyridine derivative mediated neurogenesis

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired